These results demonstrate that the PERK-eIF2α-CHOP branch of UPR in neurons plays an important role in autoimmune-induced neurodegeneration, and that combined inhibition of this pathway and activation of the XBP-1 pathway is a promising therapeutic approach for MS. This evidence concerns the gene EIF2A and myeloid sarcoma.